Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma. (26th May 2022)

• Record Type: Journal Article
• Authors: Guo, Ya; Zhang, Yin Bin; Li, Yi; Su, Wang Hui; He, Shan; Pan, Shu Pei; Xu, Kun; Kou, Wei Hua
• Other Names: Falzone Luca Academic Editor.
• Is Part Of: International journal of genomics. Volume 2022(2022)
• Publication Date: 2022-05-26
• Subjects: Genomes -- Periodicals; Genomics -- Periodicals; Cytogenetics -- Periodicals; Genomics; Genome; Molecular Biology; Cytogenetics; Genomes; Genomics; Periodicals; 572.86
• DOI: 10.1155/2022/3342666
• Languages: English
• ISSNs: 2314-436X

Abstract

Abstract : Aim . We aim to develop a signature that could accurately predict prognosis and evaluate the response to immune checkpoint blockade (ICB) in bladder urothelial carcinoma (BLCA). Methods . Based on comprehensive analysis of public database, we identified prognosis-related hub genes and investigated their predictive values for the ICB response in BLCA. Results . Among 69 common DEGs, three genes (AURKA, BIRC5, and CKS1B) were associated with poor prognosis, and which were related to histological subtypes, TP53 mutation status, and the C2 (IFN-gamma dominant) subtype. Three genes and their related risk model can effectively predict the response of immunotherapy. Their related drugs were identified through analysis of drug bank database. Conclusions . Three genes could predict prognosis and evaluate the response to ICB in BLCA.